CIRM awarded $26 million to advance clinical research across cancer, heart conditions, and rare diseases
On Jun. 28, 2024, the California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated…
Biotechnology | CRISPR | Disease | FDA | Life Science News | Therapeutics
CRISPR Therapeutics announced FDA approval of CASGEVY for treatment of ransfusion-dependent beta thalassemia
On Jan. 16, 2024, the U.S. Food and Drug Administration (FDA) announced it had approved CRISPR Therapeutics’ CASGEVY…
Biotechnology | CRISPR | FDA | Genomics | Life Science News | Therapeutics
Vertex and CRISPR Therapeutics announced U.S. FDA approval of CASGEVY for treatment of sickle Cell disease
On Dec. 8, 2023, Vertex Pharmaceuticals and CRISPR Therapeutics announced that the U.S. Food and Drug Administration (FDA)…
CIRM invested $10 million to build California Cell and Gene Therapy Manufacturing Network
On May 31, 2023, the California Institute for Regenerative Medicine (CIRM) awarded $10 million to five facilities as…
U.S. FDA approves cell therapy for patients with blood cancers to reduce risk of infection after stem cell transplantation
On Apr. 17, 2023, the U.S. FDA approved Gamida Cell’s Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord…
Study of Penn patients with decade-long leukemia remissions after CAR T cell therapy revealed new details about persistence of personalized ‘Living Drug’ cells
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
FDA approved Kiteï¾’s Tecartusï¾® as first and only Car T for adults with Relapsed or Refractory B-cell ALL
On Oct. 1, 2021, Kite, a Gilead Company, announced the U.S. Food and Drug Administration had granted approval…
Thermo Fisher and University of California, San Francisco announced cell therapy cGMP manufacturing and collaboration center
On May 19, 2021, Thermo Fisher Scientific and the University of California, San Francisco (UCSF) announced they have…
FDA approved Bristol Myers Squibbï¾’s and bluebird bioï¾’s Abecma for Relapsed or Refractory Multiple Myeloma
On Mar. 26, 2021, Bristol Myers Squibb and bluebird bio announced that the FDA had approved Abecma (idecabtagene…
FDA approved new treatment for adults with relapsed or refractory large-B-Cell lymphoma
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
New CAR T-Cell therapy approved and available at Roswell Park for lymphoma patients
On Oct. 13, 2020, Roswell Park Comprehensive Cancer Center announced that it had been approved to administer the…
Lineage Cell Therapeutics to apply allogeneic dendritic cell therapy program to COVID-19 vaccine development
On May 6, 2020, Lineage Cell Therapeutics announced that it has applied for grant funding from the California…
Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…
Caladrius Biosciences planned to assess CLBS119 cell therapy for repair of COVID-19 induced lung damage
On Apr. 23, 2020, Caladrius Biosciences announced the FDA has authorized its investigational new drug application for the…
Pluristem treated first COVID-19 patient in US under FDA single patient expanded access program
On Apr. 13, 2020, Pluristem Therapeutics announced it has treated its first patient suffering from COVID-19 complications in…
Israel weighed “compassionate use” of Pluristem therapy for COVID-19
On Mar. 17, 2020, Israel’s Health Ministry announced that it had approved a request by Pluristem Therapeutics to…
UPenn completed exclusive R&D alliance with Novartis
On Sept. 12, 2019, UPenn completed its exclusive, 7-year research and development alliance with Novartis, that spawned the…
Biotechnology | Disease | Life Science History | Life Science News | Non-Profit Research | Therapeutics
City of Hope, TGen announced letter of intent to build cell therapy manufacturing facility in Phoenix area
On Nov. 1, 2018, City of Hope, and its affiliate, Translational Genomics Research Institute (TGen), announced a letter…
Biotechnology | Disease | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics
Siteman Cancer Center became one of the first cancer centers nationwide to offer newly approved CAR-T cell therapy called Yescarta
On Oct. 18, 2017, the Siteman Cancer Center became one of the first cancer centers nationwide to offer…